DW34
DW34 is an orally active pan-BRD4-D1 biased inhibitor with additional BRD4-D2 inhibitive activity. DW34 displays comparable inhibitive efficacy to I-BET151 (EC50 = 0.16 μM) with low nanomolar EC50 values of 0.14 μM. DW34 significantly reduces liver inflammation induced by LPS (HY-D1056) and APAP (HY-66005) via reducing chemokine expression and cellular necrosis[1].
Product Specifications
CAS Number
2758171-54-7
UNSPSC
12352005
Target
Epigenetic Reader Domain; Necroptosis
Related Pathways
Apoptosis; Epigenetics
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CC1=C(N(C2CCN(CC2)CCN(C)C)N=N1)C3=CC=CC(OC4=CC(C)=CC(C)=C4)=N3
Molecular Formula
C25H34N6O
Molecular Weight
434.58
References & Citations
[1]Doskey LC, et al. Efficacy and Toxicity Analysis of Selective BET Bromodomain Inhibitors in Models of Inflammatory Liver Disease. J Med Chem. 2025 Apr 24;68 (8) :8091-8105.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
123695-ML405 100 µL
ATP1B2 (Sodium/Potassium-transporting ATPase Subunit beta-2, Sodium/Potassium-dependent ATPase Subunit beta-2) (MaxLight 405) discontinued
Sign In for Pricing
View Details 